Focus on empagliflozin : post hoc analyses of the cardiovascular outcome trial EMPA-REG OUTCOME
Abstract
EMPA-REG OUTCOME trial studied the cardiovascular safety of empagliflozin, a sodium-glucose cotransporter type 2 (SGLT2) inhibitor, compared to placebo, in patients with type 2 diabetes and high cardiovascular risk. It showed a significant reduction of major cardiovascular events (-14 %), cardiovascular mortality (-38 %), all-cause death (-32 %), hospitalisations for heart failure (-35 %) and progression of renal disease (-39 %). This article proposes an update, almost 4 years after the original publication, of recent post hoc analyses of this landmark study.
L’étude EMPA-REG OUTCOME a étudié la sécurité cardiovasculaire de l’empagliflozine, un inhibiteur sélectif des cotransporteurs sodium-glucose de type 2 (SGLT2), en comparaison à un placebo, chez des patients diabétiques de type 2 à haut risque cardiovasculaire. Elle a montré une réduction significative des événements cardiovasculaires majeurs (-14 %), de la mortalité cardiovasculaire (-38 %), de la mortalité globale (-32 %), des hospitalisations pour insuffisance cardiaque (-35 %) et des événements rénaux (-39 %). Cet article fait le point, 4 ans après la publication originale, en rapportant les résultats des nombreuses analyses post hoc qui ont été réalisées depuis lors à propos de cette étude pivot. e.
How strong is the evidence?
Evidence Hub reads this as a secondary / pooled analysis, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence.
Read the paper
Related studies
- Risk Factors for Coronavirus Disease 2019 (COVID-19) Death in a Population Cohort Study from the Western Cape Province, South Africa
- Global and regional estimates of genital human papillomavirus prevalence among men: a systematic review and meta-analysis
- A methodology for assessing deployment trauma and its consequences in OEF/OIF/OND veterans: The TRACTS longitudinal prospective cohort study
- Post‑COVID‑19 Syndrome in Outpatients: a Cohort Study
- Factors Influencing Primary and Secondary Implant Stability—A Retrospective Cohort Study with 582 Implants in 272 Patients
- Electroacupuncture for Painful Diabetic Peripheral Neuropathy: A Multicenter, Randomized, Assessor-Blinded, Controlled Trial
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.